We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions.
prevention of esophageal varices in MASH cirrhosis (NAVIGATE)(Phase 2/3)
MASH with advanced fibrosis (NASH-FX)(Phase 2)
MASH with compensated cirrhosis and portal hypertension (NASH-CX)(Phase 2)
advanced/metastatic head and neck cancer (with PD-1 inhibitor)(Phase 1)
Status note Galectin-3 inhibitor. NAVIGATE Phase 2b/3 (357 patients randomized by Feb 2023) for prevention of esophageal varices in MASH cirrhosis; stage 1 analyzed as stand-alone trial with topline presented December 2024. Filing states NAVIGATE was the company's only active clinical trial and it currently has no plans or funding to undertake another clinical trial. Head and neck cancer Phase 2 commencement dependent on financing (IND filed 2022, Study May Proceed received).
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.